Innoviva (INVA) Non Operating Income (2013 - 2026)
Innoviva posted quarterly Non Operating Income of -$366000.0 for Q1 2026, up 63.25% year-on-year from -$224191.9 in Q1 2025, and up 23.59% on a QoQ basis from -$479000.0 in Q3 2025.
Innoviva (INVA) has 14 years of Non Operating Income data on file, last reported at -$366000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income rose 63.25% year-over-year to -$366000.0; the trailing twelve-month figure through Mar 2026 stood at -$2.6 million (up 36.44% YoY), and the FY2025 full-year result was -$2.9 million, up 4.44% from the prior year.
- Non Operating Income for Q1 2026 stood at -$366000.0, up from -$479000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $28000.0 in Q3 2022 and bottomed at -$1.9 million in Q2 2023.
- The 5-year median for Non Operating Income is -$914000.0 (2024), against an average of -$829230.8.
- The widest annual swing landed in 2022, when Non Operating Income jumped 104.29%; it then tumbled 3839.29% in 2023.
- A 5-year view of Non Operating Income shows it stood at $28000.0 in 2022, then sank by 3839.29% to -$1.0 million in 2023, then gained by 12.7% to -$914000.0 in 2024, then surged by 47.59% to -$479000.0 in 2025, then increased by 23.59% to -$366000.0 in 2026.
- The last three Non Operating Income figures came in at -$366000.0 (Q1 2026), -$479000.0 (Q3 2025), and -$777000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | -366,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -366,000.00 |
| Sep 30, 2025 | -479,000.00 |
| Jun 30, 2025 | -777,000.00 |
| Mar 31, 2025 | -996,000.00 |
| Sep 30, 2024 | -914,000.00 |
| Jun 30, 2024 | -973,000.00 |
| Mar 31, 2024 | -1.24 Mn |
| Sep 30, 2023 | -1.05 Mn |
| Jun 30, 2023 | -1.90 Mn |
| Mar 31, 2023 | -1.35 Mn |
| Sep 30, 2022 | 28,000.00 |
| Jun 30, 2022 | -528,000.00 |
| Mar 31, 2022 | -250,000.00 |
| Sep 30, 2021 | -652,000.00 |
| Jun 30, 2021 | -951,000.00 |
| Mar 31, 2021 | -433,000.00 |
| Dec 31, 2020 | -433,000.00 |
| Sep 30, 2020 | -13,000.00 |
| Jun 30, 2020 | 30,000.00 |
| Mar 31, 2020 | 68,000.00 |
| Dec 31, 2019 | -223,000.00 |
| Sep 30, 2019 | -115,000.00 |
| Jun 30, 2019 | -8,000.00 |
| Mar 31, 2019 | 1,000.00 |
| Dec 31, 2018 | -16,000.00 |
| Sep 30, 2018 | -2.63 Mn |
| Jun 30, 2018 | 39,000.00 |
| Mar 31, 2018 | -3.10 Mn |
| Dec 31, 2017 | 70,000.00 |
| Sep 30, 2017 | -6.37 Mn |
| Jun 30, 2017 | -786,000.00 |
| Mar 31, 2017 | 47,000.00 |
| Dec 31, 2016 | 734,000.00 |
| Sep 30, 2016 | 56,000.00 |
| Jun 30, 2016 | 1.72 Mn |
| Mar 31, 2016 | -32,000.00 |
| Dec 31, 2015 | 3,000.00 |
| Sep 30, 2015 | -45,000.00 |
| Jun 30, 2015 | -16,000.00 |
| Mar 31, 2015 | 1.18 Mn |
| Dec 31, 2014 | -3.61 Mn |
| Sep 30, 2014 | 255,000.00 |
| Jun 30, 2014 | 83,000.00 |
| Mar 31, 2014 | -3,000.00 |
| Dec 31, 2013 | -2,000.00 |
| Sep 30, 2013 | -37,000.00 |
| Jun 30, 2013 | 8.19 Mn |
| Mar 31, 2013 | -1.42 Mn |